Vascular dysfunction can lead to many health problems including hypertension and heart disease. The complexities of vascular dysfunction and vascular disorder-related diseases have prompted the search for many new biologically active compounds in the efforts of resolving the problems. Previous studies have shown that Amaryllidaceae alkaloids exert multiple biological activities, including the vasorelaxation effect. Crinum amabile, which is a family member of Amaryllidaceae, is believed to possess a promising pharmacological activity as a vasorelaxant. The vasorelaxation activities of Crinum amabile extracts and fractions were determined using in vitro models of phenylephrine pre-contracted intact and denuded rat aortic rings. The mechanistic pathways of vasorelaxation were investigated by pre-treatment of endothelium-intact rat aortic rings with L-NG Nitro Arginine Methyl Ester (L-NAME), methylene blue (MB), indomethacin, atropine and propranolol, respectively. The results showed that chloroform extract (CE) of Crinum amabile exhibited the highest vasorelaxation activity, and further fractionation of CE found that its F5 fraction exerted the strongest activity. An in-depth study on the mechanistic pathway revealed that the endothelium-dependent vasorelaxation induced by F5 fraction was primarily achieved through stimulation of prostaglandin (PGI2) production and partially associated with NO/cGMP activation pathway. Findings from this study suggest that Crinum amabile can serve as a promising candidate for the discovery and development of the new vasorelaxant drug.

中文翻译：

---

文殊兰氯仿提取物 F5 部分的内皮依赖性血管舒张作用

血管功能障碍可导致许多健康问题，包括高血压和心脏病。血管功能障碍和血管疾病相关疾病的复杂性促使人们寻找许多新的生物活性化合物来努力解决这些问题。先前的研究表明石蒜科生物碱具有多种生物活性，包括血管舒张作用。Crinum amabile 是石蒜科的一个家族成员，被认为具有作为血管舒张剂的有前途的药理活性。使用去氧肾上腺素预收缩完整和裸露的大鼠主动脉环的体外模型测定文殊兰提取物和级分的血管舒张活性。通过分别用 L-NG 硝基精氨酸甲酯 (L-NAME)、亚甲基蓝 (MB)、吲哚美辛、阿托品和普萘洛尔预处理内皮完整的大鼠主动脉环，研究血管舒张的机制途径。结果表明，文殊兰的氯仿提取物(CE)具有最高的舒血管活性，进一步分馏CE发现其F5级分的活性最强。对机制途径的深入研究表明，F5组分诱导的内皮依赖性血管舒张主要是通过刺激前列腺素（PGI2）产生来实现的，部分与NO/cGMP激活途径有关。这项研究的结果表明文殊兰可以作为发现和开发新型血管舒张药物的有希望的候选者。